Navigation Links
Algenol Biofuels Appoints Chief Science Officer
Date:9/8/2008

Dr. John Coleman to Lead Scientific Operations

NAPLES, Fla., Sept. 8 /PRNewswire/ -- Algenol Biofuels, developers of DIRECT TO ETHANOL(TM), the most advanced third generation biofuels technology, today announced the appointment of Dr. John R. Coleman as Chief Science Officer. Dr. Coleman, currently the Vice-Principal Research and Graduate Studies at the University of Toronto, has over 20 years of experience in the fields of molecular biology and biochemistry of photosynthetic carbon metabolism in higher plants and cyanobacteria.

"I am excited to join Algenol as they enter the commercialization phase of their development," commented Dr. John R. Coleman, Chief Science Officer, Algenol Biofuels. "Based upon over 20 years of experience in photosynthesis research, I believe Algenol's Direct to Ethanol(TM) process is able to deliver several key benefits over the many current alternatives for producing ethanol and algae-based biodiesel. Although Algenol's process is already highly efficient and capable of producing a low cost ethanol, I am confident we can continue to further enhance the efficiency of this process."

Prior to his current post at the University of Toronto, Dr. Coleman was Chair of the Department of Botany from 1998 to 2004 and played a primary role in the formation of the new Department of Cell and Systems Biology in 2006.

"We are thrilled that Dr. Coleman has joined Algenol to help us in our development and production of third-generation biofuels, which leverages the photosynthetic process to produce ethanol in one step," said Paul Woods, co-founder and CEO of Algenol Biofuels. "His demonstrated leadership in this area and over 20 years of experience with algae will be a great advantage as we strive to address the world's growing transportation fuel needs."

Dr. Coleman received his Ph.D. in plant biochemistry from York University in 1981 and continued his studies in plant molecular biology as a postdoctoral fellow in the Department of Plant Biology, Carnegie Institution of Washington at Stanford University prior to joining the University of Toronto in 1984.

About Algenol Biofuels

Algenol Biofuels, Inc., a privately owned company, was founded in early 2006 and is engaged in broad research and development efforts to develop industrial-scale production systems to make ethanol from algae. The company's DIRECT TO ETHANOL(TM) process is the most advanced third generation biofuels technology that produces industrial-scale, low cost ethanol using algae, sunlight, CO2 and seawater. It is the only end-to-end commercial process that stabilizes and reduces CO2 levels. Algenol is slated for commercial sales of ethanol in 2009. For more information, please visit http://www.algenolbiofuels.com.


'/>"/>
SOURCE Algenol Biofuels, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
2. New Generation Biofuels Set to Join Russell Microcap Index
3. NexGen Biofuels Ltd. Announces Plans to Replace its CFO With Local CFO
4. Performance Plants Establishes U.S. Biofuels Facility
5. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
6. NexGen Biofuels Ltd. Announces Trading on OTC Bulletin Board
7. NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
8. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
9. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
10. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
11. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):